2013-02-21 08:38:45 -
The Board of Directors of Swedish Orphan Biovitrum AB (Sobi) has decided to
issue an additional nominal amount of up to SEK 200 million under the current
bond loan with a loan frame of SEK 1 billion. Sobi has previously issued SEK
600 million in nominal amount under the bond loan which is admitted to trading
on NASDAQ OMX Stockholm.
The additional amount is intended to be placed with selected investors and the
issue proceeds will be used to ensure that Sobi can meet the opportunities
presented by the pace and scale of Sobi's Haemophilia programs. The bond loan
has a floating interest of 3 months Stibor + 500 bps with maturity in 2017. The
full terms and conditions of the bond loan are available on Sobi's webpage
of the issue will be announced following completion.
Nordea Bank is acting as financial advisor to Sobi and Bookrunner in conjunction
with the issuance.
For further information, please contact:
Investor Relations: Jörgen Winroth
Phone: +46-(0)8-697 20 00
About Swedish Orphan Biovitrum AB (Sobi)
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
The above information has been made public in accordance with the Swedish
Financial Instruments Trading Act. The information was released for public
distribution on 21 February 2013 at 8.35 a.m. CET.
Sobi Press Release on February 21, 2013, in PDF format:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE